| Type I interferon activates MHC class I-dressed CD11b+ conventional dendritic cells to promote protective anti-tumor CD8+ T cell immunity E Duong, TB Fessenden, E Lutz, T Dinter, L Yim, S Blatt, A Bhutkar, ... Immunity 55 (2), 308-323. e9, 2022 | 246 | 2022 |
| Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer S Kregel, JL Chen, W Tom, V Krishnan, J Kach, H Brechka, TB Fessenden, ... Oncotarget 7 (18), 26259, 2016 | 121 | 2016 |
| Deciphering the immunopeptidome in vivo reveals new tumour antigens AM Jaeger, LE Stopfer, R Ahn, EA Sanders, DA Sandel, WA Freed-Pastor, ... Nature 607 (7917), 149-155, 2022 | 70 | 2022 |
| Cell-extrinsic consequences of epithelial stress: activation of protumorigenic tissue phenotypes CA Fordyce, KT Patten, TB Fessenden, RA DeFilippis, ES Hwang, J Zhao, ... Breast Cancer Research 14, 1-19, 2012 | 59 | 2012 |
| Tissue site and the cancer immunity cycle BL Horton, TB Fessenden, S Spranger Trends in cancer 5 (10), 593-603, 2019 | 51 | 2019 |
| DNA damage drives an activin a–dependent induction of cyclooxygenase-2 in premalignant cells and lesions C Fordyce, T Fessenden, C Pickering, J Jung, V Singla, H Berman, T Tlsty Cancer Prevention Research 3 (2), 190-201, 2010 | 50 | 2010 |
| Engineering kinetics of TLR7/8 agonist release from bottlebrush prodrugs enables tumor-focused immune stimulation SH Bhagchandani, F Vohidov, LE Milling, EY Tong, CM Brown, ... Science Advances 9 (16), eadg2239, 2023 | 33 | 2023 |
| Dia1-dependent adhesions are required by epithelial tissues to initiate invasion TB Fessenden, Y Beckham, M Perez-Neut, G Ramirez-San Juan, ... Journal of Cell Biology 217 (4), 1485-1502, 2018 | 32 | 2018 |
| A team effort: natural killer cells on the first leg of the tumor immunity relay race TB Fessenden, E Duong, S Spranger Journal for immunotherapy of cancer 6, 1-3, 2018 | 26 | 2018 |
| Dendritic cell-mediated cross presentation of tumor-derived peptides is biased against plasma membrane proteins TB Fessenden, LE Stopfer, F Chatterjee, J Zulueta, J Mesfin, TC Dumit, ... Journal for ImmunoTherapy of Cancer 10 (7), e004159, 2022 | 11 | 2022 |
| Deciphering the tumor-specific immunopeptidome in vivo with genetically engineered mouse models AM Jaeger, LE Stopfer, EA Sanders, DA Sandel, WA Freed-Pastor, ... bioRxiv, 2021.06. 30.450516, 2021 | 3 | 2021 |
| You are the most valuable reagent in the lab: mental health before and during the pandemic T Fessenden Molecular Biology of the Cell 32 (19), 1795-1796, 2021 | 1 | 2021 |
| Cytoskeletal Control of Tissue Shape Changes TB Fessenden The University of Chicago, 2017 | 1 | 2017 |
| Chatter ee TB Fessenden, LE Stopfer F., Zulueta,., Mesfin,., Dumit, TC,… Spranger, S, 2022 | | 2022 |
| 766 Toward safe, systemic delivery of synthetic TLR7/8 agonists using Bottlebrush Prodrugs (BPDs) S Bhagchandani, L Milling, B Liu, T Fessenden, S Spranger, J Johnson, ... Journal for ImmunoTherapy of Cancer 9 (Suppl 2), A801-A801, 2021 | | 2021 |
| 683 Type-I-interferon activates cross-dressed CD11b+ conventional dendritic cells to enhance anti-tumor immunity E Duong, T Fessenden, E Lutz, T Dinter, L Yim, S Blatt, A Bhutkar, ... Journal for ImmunoTherapy of Cancer 9 (Suppl 2), 2021 | | 2021 |
| Deciphering the tumor-specific immunopeptidome in vivo with genetically engineered mouse models T Jacks, A Jaeger, L Stopfer, E Sanders, D Sandel, W Freed-Pastor, ... | | 2021 |
| 538 Harnessing cross-dressing dendritic cells to strengthen anti-tumor immunity E Duong, T Fessenden, A Bhutkar, S Spranger Journal for ImmunoTherapy of Cancer 8 (Suppl 3), 2020 | | 2020 |
| Up-Goer Five challenge: cell biology T Fessenden Authorea Preprints, 2017 | | 2017 |
| Formin-Dependent Adhesions are Required for Invasion by Epithelial Tissues TB Fessenden, Y Beckham, M Perez-Neut, AH Chourasia, KF Macleod, ... bioRxiv, 124297, 2017 | | 2017 |
Patrick W OakesLoyola University ChicagoEmail được xác minh tại luc.edu